Saturday, December 5, 2020
News

Cyberattack on Dr Reddy's Labs sharp reminder to strengthen digital infrastructure: Analysts

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

New Delhi | Saturday, 2020 6:15:06 AM IST
The cyberattack on Dr Reddy's Labs came as a sharp reminder to strengthen its digital infrastructure and tighten cyber security control measures, according to analysts.

According to a report by HSBC, damage control and restoration of operations is crucial. It said Dr Reddy's is a front runner among peers in terms of investing for digital transformation initiatives as well as for new age cyber securities technologies.

"Thus, the cyberattack came as a sharp reminder to strengthen its digital infrastructure and tighten cyber security control measures. While it expects no major operational impact, a quick update on damage control and restoration of operations will in our view be crucial to validate resilience of its systems," the report added.

Dr Reddy's faced a major data breach yesterday which triggered a shutdown of its key facilities. The company experienced data breaches in servers in the UK, the US, India, Brazil and Russia. Afterwards, the company released a statement which said that in the wake of a detected cyberattack, it had isolated all data centre services to implement preventative measures. Dr Reddy's anticipates all services to be up within 24 hours and does not expect any major impact on operations due to the cyberattack.

Most of the Indian pharma manufacturers are increasingly focused on digitisation and process automation to improve operational efficiencies.

With increasing digitisation, data breaches and cyberattacks are common place, with the pharmaceuticals industry one of the sectors most impacted, after healthcare, energy and finance as per a study by Ponemon Institute (a Michigan-based research institute dedicated to data privacy, protection, and information security policy), and IBM Security.

For example, Merck faced a major cyberattack in June 2017 that led to disruption of its worldwide operations and sales losses of $260 million due to nonfulfillment of orders, and it incurred incremental costs (incl. remediation costs) of $285 million in 2017.

"The risk of cyberattacks on the pharma industry is further amplified by remote working during the COVID-19 pandemic. Thus, pharma manufacturers (incl. DRRD) need to invest further and strengthen cyber security systems to avoid or minimise operational disruptions, high costs of control, and to contain damages and any potential lawsuits or regulatory penalties," the report said.

--IANS san/pgh

( 382 Words)

2020-10-24-00:26:03 (IANS)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE BUSINESS NEWS
United States and India discuss IP-led s...
As per ICMR directives, REME - PHI techn...
Run disclaimer with fantasy sports ads: ...
Inflationary woes: RBI retains rates, ma...
8 out of 10 people exhibit trust in adve...
Two arrested for GST fraud of Rs 118 cro...
More...
 
INDIA WORLD ASIA
Vaccine should be given free of cost to ...
CBI books Delhi-based chemical company i...
Criminal held following encounter with p...
Resolution passed against holding local ...
3rd phase of DDC polls registers 50.53% ...
Celebrations break out in Telangana BJP ...
More...    
 
 Top Stories
UK, EU Brexit talks paused over 'si... 
Canada's Covid-19 cases surpass 400... 
Kareena, Karisma Kapoor extend birt... 
SA vs Eng: Proteas squad members te... 
Russia registers new single-day rec... 
Left parties support farmer organis... 
Dhawan turns 35, Yuvraj and Rahul l... 
As per ICMR directives, REME - PHI ...